BioXcel Therapeutics is trading at $0.07, down 37.11%, as it faces Nasdaq trading suspension and an expected move to the OTC Pink Limited Market on September 8, 2026.
- The transition follows its August 27, 2026 Chapter 11 bankruptcy filing.
- The filing reported $100 million–$500 million of liabilities and $10 million–$50 million of assets.
- With broader markets relatively mixed, company-specific trading-status and bankruptcy concerns appear central.